News
![3 Stocks That Can Help You to Get Richer in 2024 and Beyond: https://g.foolcdn.com/editorial/images/783604/getty-business-traveler-with-shoulder-bag-smiling-happy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzdoYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4927670e6b56e37a43a3a0c75ee73f86923d39a8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/getty-business-traveler-with-shoulder-bag-smiling-happy.jpg?locale=us)
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment
![Beware, Wegovy -- Pfizer Is Working on a Competitor: https://g.foolcdn.com/editorial/images/783593/patient-taking-medicine.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzNnYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--54796c145a714d06af8f374daf18ce0ac42cebd5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-taking-medicine.jpg?locale=us)
Beware, Wegovy -- Pfizer Is Working on a Competitor
Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, Pfizer (NYSE: PFE) is the one Americans associate most with this
![3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/784254/gettyimages-research-team-smiles-in-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODdnYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ad9b26749fd09adefc3a5a9d8e48a1f3692310ff/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-research-team-smiles-in-lab.jpg?locale=us)
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant
![Why AT&T Stock Is Rising Today: https://g.foolcdn.com/editorial/images/784445/gettyimages-1281453458.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUxnYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--171aa8fcd076bea0fbd4a5d875f7ca655977a744/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1281453458.jpg?locale=us)
Why AT&T Stock Is Rising Today
Shares of the telecommunications giant AT&T (NYSE: T) popped this morning after the company released second-quarter results showing strong subscriber growth and impressive free cash flow.
AT&T's
![AT&T; (T) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
AT&T; (T) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AT&T (NYSE: T)Q2 2024 Earnings CallJul 24, 2024, 8:30 a.m. ET
Operator
Source Fool.com
![This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer: https://g.foolcdn.com/editorial/images/784050/someone-measuring-a-persons-waist.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2pmYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d553bc67c6049739686fa1fd6213220cb5a63eb3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/someone-measuring-a-persons-waist.jpg?locale=us)
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
If there's one thing healthcare giant Pfizer (NYSE: PFE) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are
![This 6%-Yielding Dividend Stock Is About to Get a Boost From the Biggest IPO of 2024: https://g.foolcdn.com/editorial/images/784182/a-person-pointing-to-dollar-signs-next-to-a-chart-showing-steady-growth.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3ZkYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--16c53f888b8842832c71da269134798e9c98d491/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-pointing-to-dollar-signs-next-to-a-chart-showing-steady-growth.jpg?locale=us)
This 6%-Yielding Dividend Stock Is About to Get a Boost From the Biggest IPO of 2024
Lineage Logistics, a real estate investment trust (REIT) focused on cold storage facilities, is preparing to go public. It's seeking to raise up to $3.9 billion -- a $19.2 billion valuation --
![Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?: https://g.foolcdn.com/editorial/images/784123/scales-feet-tape-measure.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG5kYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f0379c4a9b1f39973daa526288518f929e6caf80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scales-feet-tape-measure.jpg?locale=us)
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar
![AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?: https://g.foolcdn.com/assets/images/fool/tmf-logo_400x400.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaTRFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--7b1053a3605f66e35a9c178293b2594f08cb4204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tmf-logo_400x400.png?locale=us)
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Shares of Big Pharma company AbbVie (NYSE: ABBV) inched higher recently in response to positive news from a Wall Street investment bank. BMO Capital analyst Evan Seigerman raised his price target on
![This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?: https://g.foolcdn.com/editorial/images/783933/healthcare-lab-treatment-research-scientist.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUxjYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7db84503545e19d019cc53eb3d18043333883be0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist.jpg?locale=us)
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
Watch out, Novo Nordisk and Eli Lilly. Per some new clinical-trial data it published on July 17, the massive Swiss pharmaceutical company Roche Holding (OTC: RHHBY) might have a winning weight-loss
![Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche: https://g.foolcdn.com/editorial/images/783940/two-doctors-talk-at-conference-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHZjYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b3720430a96c9621ac2ce93d23fc6c2e1c809a3c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-doctors-talk-at-conference-room.jpg?locale=us)
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss
![Is It Too Late to Buy Nvidia Stock in the Second Half of 2024?: https://g.foolcdn.com/editorial/images/783847/business-people-in-a-meeting.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN1BiYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--92eba791585026c25b235310a5c91b45f5b20457/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/business-people-in-a-meeting.jpg?locale=us)
Is It Too Late to Buy Nvidia Stock in the Second Half of 2024?
Nvidia's (NASDAQ: NVDA) stock has dropped 13% over the past month. The company's share price has fallen alongside declines in fellow chip stocks like Advanced Micro Devices, ARM Holdings, Taiwan
![Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.: https://g.foolcdn.com/editorial/images/783708/group-of-doctors-talking-on-a-meeting-in-hospital.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGpiYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1f11030f67c766186dbcf0e28683fc55c184a635/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/group-of-doctors-talking-on-a-meeting-in-hospital.jpg?locale=us)
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage
![Is Viking Therapeutics a Millionaire-Maker?: https://g.foolcdn.com/editorial/images/783729/getty-happy-person-with-cash-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMExhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d4445a9e82594b8412f559ff51b72fe6c3ba78fd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/getty-happy-person-with-cash-money.jpg?locale=us)
Is Viking Therapeutics a Millionaire-Maker?
Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally
![Why SoundHound AI Stock Plummeted Today: https://g.foolcdn.com/editorial/images/783867/gettyimages-1167797024.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0RhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cbcb089d71bc5c8b6e7ca0e98b96809ce8079e6e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1167797024.jpg?locale=us)
Why SoundHound AI Stock Plummeted Today
SoundHound AI (NASDAQ: SOUN) stock saw big sell-offs Thursday. The company's share price ended the daily session down 8.9%, according to data from S&P Global Market Intelligence.
While there wasn't
![Novartis Ag (NVS) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q2 2024 Earnings CallJul 18, 2024, 8:00 a.m. ET
Operator
Source Fool.com
![Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Abbott Laboratories (NYSE: ABT)Q2 2024 Earnings CallJul 18, 2024, 9:00 a.m. ET
Operator
Source Fool.com
![Why Novartis Stock Is Down Today Despite Topping Q2 Estimates: https://g.foolcdn.com/editorial/images/783825/getty-person-feeling-worried-looking-at-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlRaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8a0b1acc2a93e8296203e7450d6df9721239a04c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/getty-person-feeling-worried-looking-at-a-laptop.jpg?locale=us)
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than
![Collect $2,000 in Dividends Per Year by Investing $35,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/783388/a-couple-counting-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNnJZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--48f610ec3c8330f8632b0fb9cb20bbc681d613ae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-counting-money.jpg?locale=us)
Collect $2,000 in Dividends Per Year by Investing $35,000 in These 3 Stocks
Investors have been focusing on growth stocks and artificial intelligence (AI)-related investments during the past year and a half. That means that dividend stocks have made for fairly underwhelming
![2 Magnificent Stocks to Buy With $500: https://g.foolcdn.com/editorial/images/783078/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNnZZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4f6f558904f0741b349a665276e83aa348896608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=us)
2 Magnificent Stocks to Buy With $500
Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued
![Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped: https://g.foolcdn.com/editorial/images/783680/1-red-arrow-going-down-crosses-1-green-arrow-going-up.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGpZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4a7a1e51653a3cb8cb8741ea987de46431a9c465/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/1-red-arrow-going-down-crosses-1-green-arrow-going-up.jpg?locale=us)
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996.
But
![3 Absurdly Cheap Stocks to Buy and Hold for Years: https://g.foolcdn.com/editorial/images/783387/people-discussing-a-sales-report.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVRYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2de7f96251bef9e97ddf02de77a5a5403d3ef27e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/people-discussing-a-sales-report.jpg?locale=us)
3 Absurdly Cheap Stocks to Buy and Hold for Years
Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing
![Is GSK a Top Value Stock Right Now?: https://g.foolcdn.com/editorial/images/783570/cost-vs-value.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOW5YYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cd9ae99ff084c353c405f3d0f4624c8cb911ab3c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cost-vs-value.jpg?locale=us)
Is GSK a Top Value Stock Right Now?
GSK (NYSE: GSK), a global healthcare powerhouse, has been on a transformative journey since CEO Emma Walmsley took the helm in 2017. Despite its shares badly underperforming the S&P 500 under her
![Is Viking Therapeutics the Best Biotech Stock for You?: https://g.foolcdn.com/editorial/images/783175/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWZYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2a082e4f322a7cca08fb85a4104103ab61fe6a49/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
Is Viking Therapeutics the Best Biotech Stock for You?
Could 2024 be a breakout year for Viking Therapeutics (NASDAQ: VKTX)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial
![Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays: https://g.foolcdn.com/editorial/images/783531/passive-income.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXZYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--080834e5e4b165973e53a7e2eeeda3e6c1df6141/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/passive-income.jpg?locale=us)
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
Dividend stocks can be dual-threat vehicles, offering investors the best of both worlds. Specifically, these equities can act as reliable passive income generators while simultaneously possessing